LGVN Longeveron

Longeveron Chief Science Officer and Chief Medical Officer Selected as Speakers at the Global CardioVascular Clinical Trialists (CVCT) Forum

Longeveron Chief Science Officer and Chief Medical Officer Selected as Speakers at the Global CardioVascular Clinical Trialists (CVCT) Forum

MIAMI, Fla., Dec. 03, 2025 (GLOBE NEWSWIRE) -- (NASDAQ: LGVN), a clinical stage biotechnology company developing cellular therapies for life-threatening, rare pediatric and chronic aging-related conditions, today announced that its Chief Science Officer, , and Chief Medical Officer, , will speak on multiple panel discussions at the taking place December 8-10, 2025 in Washington, D.C. The CVCT Forum seeks to promote rigorous evidence generation and accelerate the global impact of cardiovascular clinical trials.

Panel Discussions – December 8, 2025

Cell Therapy Heart Failure Trials – Cells Deliver and Disease Specific Strategies

Is Cell Delivery Route Important?

Intravenous Delivery of Cells/Cell Products: The Magic Bullet? Dr. Joshua Hare

What Type of Cells?

Mesenchymal Stem Cell Therapy for Dilated Cardiomyopathy: Lessons from POSEIDON and the PATH AHEAD – Dr. Joshua Hare

How to Streamline Cell Therapy Innovation, Not Compromising the Level of Evidence

The CVCT Multi-Stakeholder Think Tank Debate

Dr. Nataliya Agafonova, Panelist

About Longeveron Inc.

Longeveron is a clinical stage biotechnology company developing regenerative medicines to address unmet medical needs. The Company’s lead investigational product is laromestrocel (Lomecel-B®), an allogeneic mesenchymal stem cell (MSC) therapy product isolated from the bone marrow of young, healthy adult donors. Laromestrocel has multiple potential mechanisms of action encompassing pro-vascular, pro-regenerative, anti-inflammatory, and tissue repair and healing effects with broad potential applications across a spectrum of disease areas. Longeveron is currently pursuing three pipeline indications: hypoplastic left heart syndrome (HLHS), Alzheimer’s disease, and Pediatric Dilated Cardiomyopathy (DCM). Laromestrocel development programs have received five distinct and important FDA designations: for the HLHS program - Orphan Drug designation, Fast Track designation, and Rare Pediatric Disease designation; and, for the AD program - Regenerative Medicine Advanced Therapy (RMAT) designation and Fast Track designation. For more information, visit  or follow Longeveron on , , and .

Investor and Media Contact:

Derek Cole

Investor Relations Advisory Solutions

Photos accompanying this announcement are available at





EN
03/12/2025

Underlying

LGVNLongeveron

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Longeveron

 PRESS RELEASE
Free
LGVN LONGEVERON

Longeveron® Granted Japan Patent for Potency Assay Methods for Assessi...

Longeveron® Granted Japan Patent for Potency Assay Methods for Assessing Human Mesenchymal Stem Cells (MSCs) The patent relates to potency assay methods for assessing human mesenchymal stem cells (MSCs) derived from bone marrow, adipose tissue, peripheral blood, a lung, a heart, amniotic fluid, inner organs, an amniotic membrane, an umbilical cord or a placenta or differentiated from induced pluripotent stem cells (IPSCs)Patent issuance contributes to Longeveron’s growing international patent portfolio protecting its clinical programs and productsLaromestrocel, Longeveron’s proprietary mese...

January 29, 2026 1 EN
 PRESS RELEASE
Free
LGVN LONGEVERON

Longeveron Announces FDA Grants Type C Meeting Ahead of Data Readout f...

Longeveron Announces FDA Grants Type C Meeting Ahead of Data Readout for Pivotal Phase 2 Clinical Trial (ELPIS II) Evaluating Treatment for Hypoplastic Left Heart Syndrome (HLHS) ELPIS II top-line trial results are anticipated in the third quarter of 2026Laromestrocel Biological License Application (BLA) submission for full traditional approval for HLHS anticipated if ELPIS II results are positiveU.S. FDA has awarded laromestrocel HLHS program Rare Pediatric Disease designation, Orphan Drug designation, and Fast Track designationLaromestrocel HLHS program has the potential to address an unm...

January 26, 2026 1 EN
 PRESS RELEASE
Free
LGVN LONGEVERON

Longeveron, Selected as a StartUp Health Alzheimer’s Disease Moonshot ...

Longeveron, Selected as a StartUp Health Alzheimer’s Disease Moonshot Company, Will Participate in StartUp Health Apollo House During JPM Healthcare Week 2026 Mission-aligned community focused on accelerating breakthroughs in Alzheimer’s disease, Parkinson’s disease and related conditionsSupported by Health Moonshot Champions, including the Alzheimer’s Drug Discovery Foundation (ADDF) and Gates VenturesApollo House, the Founders & Funders Networking Summit, to bring together founders, funders and industry leaders addressing Health Moonshots worldwideLongeveron will also be hosting meetings ...

December 29, 2025 1 EN
 PRESS RELEASE
Free
LGVN LONGEVERON

Longeveron Granted U.S. Patent for Method of Treating Female Sexual Dy...

Longeveron Granted U.S. Patent for Method of Treating Female Sexual Dysfunction Using its Proprietary Stem Cell Therapy The patent relates to methods of administering therapeutically effective amounts of isolated allogeneic mesenchymal stem cells (MSCs) to female patients with sexual dysfunction in order to increase sexual quality of lifeFemale sexual dysfunction is an extremely common unmet medical need which can have a major impact on quality of life in otherwise healthy womenLongeveron anticipates entering into licensing or partnering agreements for the potential development and commerci...

December 17, 2025 1 EN
 PRESS RELEASE
Free
LGVN LONGEVERON

Longeveron Chief Science Officer and Chief Medical Officer Selected as...

Longeveron Chief Science Officer and Chief Medical Officer Selected as Speakers at the Global CardioVascular Clinical Trialists (CVCT) Forum MIAMI, Fla., Dec. 03, 2025 (GLOBE NEWSWIRE) -- (NASDAQ: LGVN), a clinical stage biotechnology company developing cellular therapies for life-threatening, rare pediatric and chronic aging-related conditions, today announced that its Chief Science Officer, , and Chief Medical Officer, , will speak on multiple panel discussions at the taking place December 8-10, 2025 in Washington, D.C. The CVCT Forum seeks to promote rigorous evidence generation and ...

December 3, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch